AzTrials
AzTrials

Posterior Capsule OpacificationYAG-IOL-POSNCT07802145

IOL Position and Refractive Change After Nd:YAG Laser Posterior Capsulotomy

An observational study of Posterior Capsule Opacification and Pseudophakia, run by Vienna Hospital Association at 1 site in Austria.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

After cataract surgery, the thin natural membrane that holds the artificial lens in place can slowly turn cloudy. This is called posterior capsule opacification. It makes vision blurry and can cause glare. Read more about this study

Who is it for?
Ages 18 to 100 years
What is being tested?
Nd:YAG laser posterior capsulotomy, Anterior segment swept-source OCT and Swept-source optical biometry
How many people
80 participants
Where
1 siteAustria
Study dates
1 Sep 2026to Aug 2027
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Consecutive pseudophakic patients presenting to the Department of Ophthalmology, Klinik Hietzing, Vienna, Austria, with visually significant posterior capsule opacification for which Nd:YAG laser posterior capsulotomy is clinically indicated. Patients are identified through the routine clinical workflow: the cataract follow-up clinic, referrals from external ophthalmologists, and self-presentation with visual complaints consistent with posterior capsule opacification. Enrolment is consecutive and unselected with respect to IOL model, axial length, time since cataract surgery and morphology of the opacification, so that the cohort reflects the general population of pseudophakic eyes undergoing capsulotomy at the study centre. The decision to perform the capsulotomy is made independently of the study.

Who may be able to join

  • Pseudophakic eye with visually significant posterior capsule opacification for which Nd:YAG laser posterior capsulotomy is clinically indicated, defined as a subjective visual complaint attributable to the opacification (reduced visual acuity, glare or reduced contrast) together with objectively documented opacification on slit-lamp examination
  • Previous uneventful phacoemulsification with in-the-bag implantation of a posterior chamber intraocular lens; no restriction on IOL model
  • At least 3 months between the cataract surgery and the baseline study visit
  • Age 18 years or older at enrolment
  • Able to cooperate with the multi-device measurement protocol, including fixation for all three imaging devices and standardized subjective manifest refraction with Jackson cross-cylinder refinement
  • Written informed consent

Who cannot join

  • Complicated cataract surgery, including posterior capsule rupture, vitreous loss, zonular dialysis, sulcus intraocular lens placement, anterior vitrectomy, or any other deviation from standard in-the-bag implantation
  • Previous intraocular lens exchange, repositioning, or secondary piggyback implantation
  • Previous Nd:YAG posterior capsulotomy of the study eye
  • Previous corneal refractive surgery of the study eye
  • Interval intraocular surgery of the study eye since the cataract surgery, including vitrectomy, glaucoma filtering surgery and corneal transplantation, or intravitreal injection within 4 weeks of a study visit; selective laser trabeculoplasty is not an exclusion criterion
  • Active anterior segment inflammation at the baseline visit
Show all 9Show fewer
  • Clinically significant corneal pathology precluding reliable keratometry, including corneal oedema, band keratopathy, central corneal scarring, and Fuchs endothelial corneal dystrophy grade 3 or 4 with clinically evident oedema; grades 1 and 2 without oedema are eligible
  • Known intraocular lens instability before capsulotomy, including subluxation, decentration estimated above 1.0 mm, or pseudophacodonesis
  • Cognitive or physical limitations precluding standardized subjective manifest refraction

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Austria1 site
  • Augenabteilung, Klinik Hietzing, Wiener Gesundheitsverbund

    Vienna, State of Vienna, 1130

Other trials in Austria

About this study

Official title: Intraocular Lens Position Stability, Anterior Segment Parameters, and Refractive Change Following Nd:YAG Laser Posterior Capsulotomy: A Prospective Multi-Device Assessment Using Swept-Source OCT Biometry (IOLMaster 700), Anterior Segment OCT (CASIA2), and Scheimpflug Tomography (Pentacam AXL)

After cataract surgery, the thin natural membrane that holds the artificial lens in place can slowly turn cloudy. This is called posterior capsule opacification. It makes vision blurry and can cause glare. The standard treatment is a short, painless laser procedure called Nd:YAG capsulotomy, which opens a small clear window in the cloudy membrane.

Opening this membrane changes the support structure around the artificial lens. Eye doctors do not agree on what happens next. Some studies found that the lens shifts slightly backward in the eye after the laser treatment, some found that it shifts forward, and some found no movement at all. It is also unclear whether such a small shift changes how well a person sees or the strength of their glasses. One reason for these mixed results may be that each study used a different imaging device, and these devices measure the depth of the front chamber of the eye in different ways.

Read more

This study measures the position of the artificial lens in the same eye with three different imaging devices, before and after the laser treatment. The devices are called IOLMaster 700, CASIA2, and Pentacam AXL. All three take detailed pictures of the front of the eye without touching it. The study team wants to find out whether the artificial lens moves after the laser treatment, how much it moves, whether any movement changes vision or the glasses prescription, and whether the three devices give matching results.

Who can take part

People who had cataract surgery at least three months ago, who now have a cloudy membrane behind the artificial lens, and whose eye doctor has already decided that the laser treatment is needed.

What taking part involves

Taking part does not change the laser treatment in any way. The decision to perform the treatment, the technique, and the laser settings are made by the treating doctor for medical reasons and are not influenced by the study. The study only adds extra measurements before and after the treatment.

There are three study visits:

  • Visit 1, on the day of the laser treatment and before the laser is used. The extra measurements take about 30 to 45 minutes.
  • Visit 2, about one week after the treatment. The extra measurements take about 15 to 20 minutes.
  • Visit 3, about one month after the treatment. The extra measurements take about 30 to 45 minutes.

At each visit the study team checks how well you can see, measures the strength of glasses that gives you the sharpest vision, examines your eye with a slit lamp, measures the pressure inside your eye, and takes images with the imaging devices. All of these are standard eye examinations used in everyday clinical practice. Nothing is inserted into the eye, and there are no injections, no medicines, and no radiation. Drops to widen the pupil are not needed for the study.

Taking part is voluntary. You can stop at any time, without giving a reason and without any disadvantage for your medical care. Your laser treatment and all routine follow-up visits go ahead either way. There is no payment for taking part, and taking part brings no direct medical benefit. However, the detailed examination may reveal something that would not be noticed during routine follow-up, such as raised eye pressure. If this happens, you will be told and any necessary care will be arranged as part of your normal treatment at no extra cost.

Study data are stored under a study code instead of your name.

Read the detailed description

BACKGROUND AND RATIONALE

Posterior capsule opacification (PCO) is the most common long-term complication of cataract surgery, and Nd:YAG laser posterior capsulotomy is its established standard treatment. Disruption of the posterior capsule alters the mechanical environment of the capsular bag in which the intraocular lens (IOL) is fixated and may therefore affect IOL positional stability. Because IOL position determines the effective lens position, which is the dominant source of residual refractive prediction error in modern IOL power calculation, any clinically relevant positional change could translate into a measurable refractive shift.

The published evidence is conflicting. Individual studies report posterior IOL displacement with hyperopic shift, anterior displacement with myopic shift, or no measurable change, while the most comprehensive meta-analysis to date (850 eyes from 18 publications) reports population-level stability of anterior chamber depth (ACD) and spherical equivalent up to one month after capsulotomy. Subgroup-specific effects have been described in relation to corneal health status, IOL haptic design, the interval between cataract surgery and capsulotomy, and capsulotomy size.

A methodological limitation common to this literature is that every published study quantifies ACD with a single measurement device. Different technologies define ACD differently, using optical versus geometric measurement principles, corneal epithelium versus endothelium as the anterior reference surface, and device-specific segmentation algorithms. Cross-study comparison is therefore unreliable, and it remains unresolved whether the contradictory findings reflect genuine biological heterogeneity or device-dependent measurement artefact. In addition, automated three-dimensional quantification of IOL tilt and decentration by anterior segment swept-source OCT has not been systematically applied to the post-capsulotomy question, and the IOL platforms routinely implanted at European cataract centres are underrepresented in the available data.

DESIGN

Single-centre, prospective, non-interventional diagnostic cohort study using a paired within-eye pre-post comparison, in which each eye serves as its own control. Consecutive pseudophakic eyes with visually significant PCO scheduled for clinically indicated Nd:YAG capsulotomy are enrolled without pre-selection for IOL model, axial length, PCO morphology, or interval since cataract surgery. Measurement device, operator, and measurement conditions are held constant across time points, so that the paired design isolates the effect of capsulotomy from inter-device and inter-session variability. Simultaneous acquisition on three platforms at each time point additionally permits an inter-device agreement analysis for ACD change that is not achievable in a single-device study.

STUDY VISITS

Visit 1 (baseline) takes place on the day of capsulotomy, before the procedure. Visit 2 follows at one week (plus or minus 3 days) and Visit 3 at one month (plus or minus 7 days) after capsulotomy.

At the two full visits (Visit 1 and Visit 3) the following measurements are acquired in a fixed sequence designed to minimise measurement interference: uncorrected distance visual acuity; IOLMaster 700 optical biometry; CASIA2 anterior segment swept-source OCT; Pentacam AXL Scheimpflug tomography; autorefraction followed by subjective manifest refraction with Jackson cross-cylinder refinement and best-corrected distance visual acuity; and slit-lamp examination including intraocular pressure measurement. Mydriasis is not required by the protocol, and all measurements are performed under natural pupil conditions; if dilation is clinically indicated for other reasons, it is performed only after all study measurements are complete.

At Visit 2, visual acuity, manifest refraction, IOLMaster 700 biometry, slit-lamp examination and tonometry are mandatory, whereas CASIA2 and Pentacam AXL imaging is optional in order to limit patient burden at the interim visit; where performed, it follows the identical standardised protocol and contributes to the agreement analyses. At both post-capsulotomy visits the refractionist is masked to the previous refraction values to avoid anchoring bias.

PARAMETERS

CASIA2: ACD referenced to the posterior corneal surface, anterior chamber angle and volume, IOL tilt (horizontal and vertical) and decentration acquired with the post-operative cataract application, anterior, posterior and total/real keratometry, central corneal thickness, pupil parameters, quality score and analysis area.

IOLMaster 700: ACD referenced to the corneal epithelium, keratometry and total keratometry, axial length, central corneal thickness, white-to-white, pupillometry.

Pentacam AXL: ACD, SimK, total corneal refractive power at the 3.0 mm zone, true net power, posterior keratometry, pachymetry mapping, corneal irregularity indices (ISV, IVA, IHD, KI, CKI), chamber angle and volume, axial length.

Scans that do not meet the manufacturer's quality criteria are repeated once and otherwise documented as failed with the reason specified.

Historical data are extracted from the medical record for each enrolled eye: date and details of the cataract surgery including incision location and technique, implanted IOL model, power, material, optic and haptic design, optic edge geometry and, for toric IOLs, planned cylinder and alignment axis, together with the preoperative biometry and the documented postoperative course.

Capsulotomy parameters are documented immediately after the procedure: laser device, posterior offset, starting and maximum energy level, total energy delivered, number of shots, capsulotomy shape and diameter, contact lens used, peri-procedural medication, and intraprocedural observations including IOL pitting. The study neither prescribes nor modifies the capsulotomy technique, the energy settings, or the capsulotomy size, all of which remain at the discretion of the treating ophthalmologist.

ANALYSIS

The primary analysis set comprises one eye per patient, selected deterministically as the first treated eye within the study period; if both eyes are treated on the same day, the eye is selected at random using a reproducible seed. Bilateral eyes are analysed in a pre-specified sensitivity analysis using generalised estimating equations or linear mixed models to account for within-patient correlation.

The primary endpoint is tested against the null hypothesis of no change using a paired t-test, or a Wilcoxon signed-rank test where the normality assumption is not met, at a two-sided alpha of 0.05. It is the only confirmatory hypothesis specified. All secondary endpoints are explicitly classified as exploratory and hypothesis-generating; each is reported with a two-sided p value and a 95% confidence interval, without family-wise error correction, because they address heterogeneous mechanistic, descriptive and device-agreement questions rather than competing tests of a single hypothesis. Inter-device agreement is reported as estimation only, with bias, 95% limits of agreement and intraclass correlation coefficients, and without hypothesis testing. Pre-specified sensitivity analyses include restriction to corneally stable eyes, exclusion of eyes with Fuchs endothelial corneal dystrophy, exclusion of visits outside the protocol time window, and an alternative clinical relevance threshold for the primary endpoint.

The target sample size is based on the paired comparison of the primary endpoint. Published data report mean ACD changes after capsulotomy between 0.00 and 0.06 mm with within-eye standard deviations of approximately 0.05 to 0.10 mm. At a within-eye standard deviation of 0.08 mm and a two-sided alpha of 0.05, 57 eyes provide at least 80 percent power to detect a mean change of 0.03 mm, and the study is substantially overpowered for the pre-specified clinical relevance threshold. An attrition rate of approximately 10 percent is anticipated.

Reporting follows the STROBE statement for cohort studies, with STARD elements applied to the inter-database agreement analyses.

Being tested
Nd:YAG laser posterior capsulotomy, Anterior segment swept-source OCT, Swept-source optical biometry, Scheimpflug-based anterior segment tomography, Subjective manifest refraction
Keywords
Nd:YAG laser capsulotomy, Posterior capsulotomy, Anterior chamber depth, Effective lens position, Intraocular lens tilt, Intraocular lens decentration, Swept-source optical coherence tomography, Scheimpflug tomography, Optical biometry, Inter-device agreement, Refractive shift, Toric intraocular lens rotation
Medical subject headings
Pseudophakia, Refractive Errors

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nd:YAG laser posterior capsulotomyProcedure or surgery

    Routine Nd:YAG laser posterior capsulotomy performed for visually significant posterior capsule opacification according to the department's standard clinical protocol. Indication, technique, energy settings and capsulotomy size are determined by the treating ophthalmologist and are not modified by the study. Procedural parameters are documented for analysis.

  • Anterior segment swept-source OCTDiagnostic test

    Non-contact anterior segment optical coherence tomography providing anterior chamber depth, anterior chamber angle and volume, automated three-dimensional IOL tilt and decentration, corneal tomography, pachymetry and pupil parameters. Primary device for the primary outcome measure.

  • Swept-source optical biometryDiagnostic test

    on-contact optical biometry providing anterior chamber depth, keratometry, total keratometry, axial length, central corneal thickness, white-to-white and pupillometry.

  • Scheimpflug-based anterior segment tomographyDiagnostic test

    Scheimpflug-based anterior segment tomography providing anterior chamber depth, SimK, total corneal refractive power, true net power, posterior keratometry, pachymetry mapping, corneal irregularity indices, chamber angle and volume, and axial length.

  • Subjective manifest refractionDiagnostic test

    Autorefraction as starting value followed by subjective manifest refraction with Jackson cross-cylinder refinement, yielding sphere, cylinder, axis and spherical equivalent, plus uncorrected and best-corrected distance visual acuity in logMAR. The refractionist is masked to previous refraction values at the post-capsulotomy visits.

Study groups in NCT07802145
Study groupRoleWhat they receive
Pseudophakic Eyes Undergoing Nd:YAG Laser Posterior CapsulotomyPseudophakic eyes with visually significant posterior capsule opacification for which Nd:YAG laser posterior capsulotomy is clinically indicated independently of the study. Each eye is assessed with a standardized multi-device anterior segment protocol immediately before the routine procedure and at one week and one month afterwards, and serves as its own control in a paired within-eye comparison.
Receives: Procedure: Nd:YAG laser posterior capsulotomy; Diagnostic Test: Anterior segment swept-source OCT; Diagnostic Test: Swept-source optical biometry; Diagnostic Test: Scheimpflug-based anterior segment tomography; Diagnostic Test: Subjective manifest refraction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in anterior chamber depth (ACD) measured by anterior segment swept-source OCT

    ACD in millimetres, measured from the posterior corneal surface to the anterior IOL surface by automated CASIA2 segmentation. The change is calculated as ACD after capsulotomy minus ACD before capsulotomy. Positive values indicate posterior IOL displacement, negative values anterior displacement. Reported as mean change with standard deviation and 95% confidence interval, together with the proportion of eyes exceeding the pre-specified clinical relevance threshold of 0.05 mm in absolute value.

    Measured: Baseline (immediately before capsulotomy) and 1 month (plus or minus 7 days) after capsulotomy

Secondary outcomes (15)
  1. Change in IOL tilt measured by anterior segment swept-source OCT

    Horizontal and vertical IOL tilt in degrees, measured with the CASIA2 post-operative cataract application. Reported as mean change with standard deviation and as the proportion of eyes with an absolute tilt change of at least 2 degrees.

    Measured: Baseline and 1 month after capsulotomy

  2. Change in IOL decentration measured by anterior segment swept-source OCT

    IOL decentration in millimetres, measured with the CASIA2 post-operative cataract application. Reported as mean change with standard deviation and as the proportion of eyes with an absolute change of at least 0.3 mm.

    Measured: Baseline and 1 month after capsulotomy

  3. Change in spherical equivalent from standardized manifest refraction

    Spherical equivalent in dioptres, calculated as sphere plus half the cylinder from subjective manifest refraction with Jackson cross cylinder refinement. Positive change indicates hyperopic shift.

    Measured: Baseline, 1 week and 1 month after capsulotomy

  4. Proportion of eyes with a clinically relevant refractive shift

    Proportion of eyes with an absolute change in spherical equivalent of at least 0.50 dioptres, reported with Wilson 95% confidence intervals.

    Measured: 1 week and 1 month after capsulotomy

  5. Change in refractive cylinder magnitude and axis

    Cylindrical magnitude in dioptres and cylinder axis in degrees from standardized manifest refraction in plus-cylinder notation.

    Measured: Baseline, 1 week and 1 month after capsulotomy

  6. Change in uncorrected and best-corrected distance visual acuity

    UDVA and BCDVA in logMAR. Reported as mean change, as the proportion of eyes achieving BCDVA of 0.10 logMAR or better, and as the proportion gaining at least 2 logMAR lines.

    Measured: Baseline, 1 week and 1 month after capsulotomy

  7. Inter-device agreement for the change in anterior chamber depth

    Agreement of the ACD change between CASIA2, IOLMaster 700 and Pentacam AXL for each device pair, reported as Bland-Altman bias with 95% limits of agreement, intraclass correlation coefficient and the proportion of eyes in which both devices agree on the direction of change. Reported as estimation without hypothesis testing.

    Measured: Baseline to 1 month after capsulotomy

  8. Inter-device agreement for absolute anterior chamber depth

    Agreement of absolute ACD between CASIA2, IOLMaster 700 and Pentacam AXL for each device pair, reported separately at each time point as Bland-Altman bias with 95% limits of agreement and intraclass correlation coefficient.

    Measured: Baseline and 1 month after capsulotomy, analysed separately

  9. Change in keratometry

    Mean keratometry, keratometric cylinder and steep axis from IOLMaster 700, CASIA2 anterior keratometry and Pentacam AXL SimK, in dioptres and degrees. The proportion of eyes meeting the pre-specified corneal stability criterion is reported.

    Measured: Baseline and 1 month after capsulotomy

  10. Change in corneal irregularity indices

    Index of surface variance, index of vertical asymmetry, index of height decentration and keratoconus index measured by Pentacam AXL.

    Measured: Baseline and 1 month after capsulotomy

  11. Change in central corneal thickness

    Central corneal thickness in micrometres measured by CASIA2 and Pentacam AXL, with the proportion of eyes showing an increase above 10 micrometres as an indicator of endothelial stress.

    Measured: Baseline and 1 month after capsulotomy

  12. Change in anterior chamber angle and anterior chamber volume

    Anterior chamber angle in degrees and anterior chamber volume in cubic millimetres measured by CASIA2.

    Measured: Baseline and 1 month after capsulotomy

  13. Correlation between IOL positional change and refractive change

    Spearman correlation of the change in anterior chamber depth, IOL tilt and IOL decentration with the change in spherical equivalent, supplemented by multivariable linear regression with the change in spherical equivalent as dependent variable.

    Measured: Baseline to 1 month after capsulotomy

  14. Change in toric IOL alignment axis

    Change in the alignment axis of toric IOLs in degrees, assessed by CASIA2 and slit-lamp retroillumination, with the proportion of eyes showing a change of at least 5 and at least 10 degrees. Reported descriptively where the subgroup comprises fewer than 10 eyes.

    Measured: Baseline and 1 month after capsulotomy

  15. Change in intraocular pressure

    Intraocular pressure in mmHg measured by Goldmann applanation tonometry or non-contact tonometry, with the proportion of eyes above 21 mmHg and the proportion with an increase above 5 mmHg. Descriptive safety parameter.

    Measured: Baseline, 1 week and 1 month after capsulotomy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completionAug 2027 (estimated)
  4. Study completionAug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07802145
Sponsor's protocol ID
MA15-EK-26-141
Acronym
YAG-IOL-POS
Status last verified
Aug 2026
First submitted
30 Aug 2026
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in